FDA commish: First Amendment DTC defense airtight

Share this article:
FDA commissioner Andrew von Eschenbach issued a staunch First Amendment defense of DTC advertising at last week’s Center for Medicine in the Public Interest conference in Washington, DC. Asked his view on the controversy over DTC and the prospects of legislative tinkering with advertising regulation, von Eschenbach said: “As with any particular entity, whether an organization or individual, there is a right to free speech and an ability under the Constitution to free expression. We need to make sure the content is factual and accurate. FDA has role in making sure the public is continuing to get correct information.”
Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union